{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:32:15Z","timestamp":1790548335564,"version":"4.1.0"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T00:00:00Z","timestamp":1501200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0182019","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T18:12:12Z","timestamp":1501265532000},"page":"e0182019","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":50,"title":["The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson\u2019s disease"],"prefix":"10.1371","volume":"12","author":[{"given":"Joanna","family":"Schwenkgrub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-8841","authenticated-orcid":true,"given":"Malgorzata","family":"Zaremba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Joniec-Maciejak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Cudna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmara","family":"Mirowska-Guzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Kurkowska-Jastrz\u0119bska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/humu.21277","article-title":"Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update","volume":"31","author":"K Nuytemans","year":"2010","journal-title":"Hum Mutat"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"g6258","DOI":"10.1136\/bmj.g6258","article-title":"Initial management of Parkinson's disease","volume":"349","author":"CG Goetz","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/14740338.2015.988137","article-title":"Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease","volume":"14","author":"M Pilleri","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 1","key":"ref4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1353-8020(11)70066-9","article-title":"Fluoxetine protects neurons against microglial activation-mediated neurotoxicity","volume":"18","author":"F Zhang","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.neuroscience.2014.12.008","article-title":"Vinpocetine attenuates MPTP-induced motor deficit and biochemical abnormalities in Wistar rats","volume":"286","author":"S Sharma","year":"2015","journal-title":"Neuroscience"},{"issue":"1\u20133","key":"ref6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ejphar.2013.06.038","article-title":"Phosphodiesterases: Regulators of cyclic nucleotide signals and novel molecular target for movement disorders","volume":"714","author":"S Sharma","year":"2013","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1515\/REVNEURO.1993.4.2.213","article-title":"Transmembrane signalling systems in the brain of patients with Parkinson's disease","volume":"4","author":"N Nishino","year":"1993","journal-title":"Rev Neurosci"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.neuropharm.2003.09.009","article-title":"Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia","volume":"46","author":"T Mizuno","year":"2004","journal-title":"Neuropharmacology"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"TM Coskran","year":"2006","journal-title":"J Histochem Cytochem"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"V Lakics","year":"2010","journal-title":"Neuropharmacology"},{"issue":"3 Pt 1","key":"ref11","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1523\/JNEUROSCI.14-03-01251.1994","article-title":"Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation","volume":"14","author":"JW Polli","year":"1994","journal-title":"J Neurosci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuroscience.2012.09.011","article-title":"The distribution of phosphodiesterase 2A in the rat brain","volume":"226","author":"DT Stephenson","year":"2012","journal-title":"Neuroscience"},{"issue":"7","key":"ref13","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/13543784.16.7.935","article-title":"Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes","volume":"16","author":"A Ledeboer","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"T Keravis","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.nbd.2011.04.006","article-title":"PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology","volume":"43","author":"M Giorgi","year":"2011","journal-title":"Neurobiol Dis"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"e13417","DOI":"10.1371\/journal.pone.0013417","article-title":"Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington's disease","volume":"5","author":"C Giampa","year":"2010","journal-title":"PloS one"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"CJ Schmidt","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.expneurol.2007.02.010","article-title":"Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV","volume":"211","author":"L Yang","year":"2008","journal-title":"Exp Neurol"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1476-5381.2009.00170.x","article-title":"Dual PDE3\/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease","volume":"157","author":"KH Banner","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"17","key":"ref20","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1517\/14656560903426189","article-title":"Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease","volume":"10","author":"P Rolan","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/1871524914666141226103421","article-title":"Regulation of dopamine signaling in the striatum by phosphodiesterase inhibitors: novel therapeutics to treat neurological and psychiatric disorders","volume":"14","author":"AD Ramirez","year":"2014","journal-title":"Cent Nerv Syst Agents Med Chem"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/odi.12275","article-title":"Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets","volume":"21","author":"F Ahmad","year":"2015","journal-title":"Oral Dis"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"e0117705","DOI":"10.1371\/journal.pone.0117705","article-title":"Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis","volume":"10","author":"HM Vesterinen","year":"2015","journal-title":"PloS one"},{"issue":"25","key":"ref24","doi-asserted-by":"crossref","first-page":"11313","DOI":"10.1073\/pnas.1002716107","article-title":"Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast","volume":"107","author":"Y Cho","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1017\/S1740925X0700035X","article-title":"The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain","volume":"2","author":"A Ledeboer","year":"2006","journal-title":"Neuron Glia Biol"},{"issue":"6\u20137","key":"ref26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1440-1681.1996.tb02772.x","article-title":"Ibudilast protects against neuronal damage induced by glutamate in cultured hippocampal neurons","volume":"23","author":"Y Tominaga","year":"1996","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1471-4159.2000.740633.x","article-title":"Cyclic GMP\/cyclic GMP-dependent protein kinase system prevents excitotoxicity in an immortalized oligodendroglial cell line","volume":"74","author":"A Yoshioka","year":"2000","journal-title":"J Neurochem"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bjp.0704146","article-title":"Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model","volume":"133","author":"K Takuma","year":"2001","journal-title":"Br J Pharmacol"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.brainres.2003.08.028","article-title":"Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat","volume":"992","author":"H Wakita","year":"2003","journal-title":"Brain Res"},{"issue":"1\u20132","key":"ref30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0165-5728(98)00251-3","article-title":"Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats","volume":"95","author":"T Fujimoto","year":"1999","journal-title":"J Neuroimmunol"},{"issue":"8\u20139","key":"ref31","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/BF01291788","article-title":"Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man","volume":"103","author":"M Gerlach","year":"1996","journal-title":"J Neural Transm (Vienna)"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"W Dauer","year":"2003","journal-title":"Neuron"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3892\/etm.2013.1413","article-title":"Lobeline shows protective effects against MPTP-induced dopaminergic neuron death and attenuates behavior deficits in animals","volume":"7","author":"CY Li","year":"2014","journal-title":"Exp Ther Med"},{"issue":"4","key":"ref34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1006\/phrs.2002.0949","article-title":"Effects of ibudilast on hippocampal long-term potentiation and passive avoidance responses in rats with transient cerebral ischemia","volume":"45","author":"M Yoshioka","year":"2002","journal-title":"Pharmacol Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.pbb.2014.07.006","article-title":"Pretreatment with antiasthmatic drug ibudilast ameliorates Abeta 1-42-induced memory impairment and neurotoxicity in mice","volume":"124","author":"H Wang","year":"2014","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.55782\/ane-2003-1461","article-title":"Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease","volume":"63","author":"A Ciesielska","year":"2003","journal-title":"Acta Neurobiol Exp (Wars)"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2007.07.004","article-title":"Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention","volume":"208","author":"MG Tansey","year":"2007","journal-title":"Exp Neurol"},{"issue":"8","key":"ref38","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1567-5769(02)00078-4","article-title":"Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice","volume":"2","author":"I Kurkowska-Jastrzebska","year":"2002","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"ref39","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.intimp.2009.03.003","article-title":"Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease","volume":"9","author":"I Kurkowska-Jastrzebska","year":"2009","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0006-8993(02)04085-4","article-title":"Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL\/6 mice","volume":"964","author":"S Sugama","year":"2003","journal-title":"Brain Res"},{"issue":"11","key":"ref41","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00011-009-0026-6","article-title":"The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson's disease","volume":"58","author":"A Ciesielska","year":"2009","journal-title":"Inflamm Res"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0162-3109(98)00022-8","article-title":"Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"39","author":"M Kohutnicka","year":"1998","journal-title":"Immunopharmacology"},{"issue":"1\u20132","key":"ref43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0165-5728(99)00187-3","article-title":"Interleukin-6 expression and regulation in astrocytes","volume":"100","author":"NJ Van Wagoner","year":"1999","journal-title":"J Neuroimmunol"},{"issue":"8","key":"ref44","first-page":"Ra165","article-title":"Immune processes in the pathogenesis of Parkinson's disease\u2014a potential role for microglia and nitric oxide","volume":"8","author":"A Czlonkowska","year":"2002","journal-title":"Med Sci Monit"},{"issue":"4","key":"ref45","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.pharep.2014.03.008","article-title":"The influence of AAV2-mediated gene transfer of human IL-10 on neurodegeneration and immune response in a murine model of Parkinson's disease","volume":"66","author":"I Joniec-Maciejak","year":"2014","journal-title":"Pharmacol Rep"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1734-1140(13)70962-9","article-title":"Effect of human interleukin-10 on the expression of nitric oxide synthases in the MPTP-based model of Parkinson's disease","volume":"65","author":"J Schwenkgrub","year":"2013","journal-title":"Pharmacol Rep"},{"issue":"5","key":"ref47","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S1734-1140(13)71480-4","article-title":"Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson's disease","volume":"65","author":"M Swiatkiewicz","year":"2013","journal-title":"Pharmacol Rep"},{"issue":"10","key":"ref48","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/QAD.0000000000000291","article-title":"Ibudilast (AV411), and its AV1013 analog, reduce HIV-1 replication and neuronal death induced by HIV-1 and morphine","volume":"28","author":"N El-Hage","year":"2014","journal-title":"AIDS"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.nbd.2016.05.002","article-title":"The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling","volume":"93","author":"JL Cueva Vargas","year":"2016","journal-title":"Neurobiol Dis"},{"issue":"1","key":"ref50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00001756-199512000-00035","article-title":"GDNF reduces apoptosis in dopaminergic neurons in vitro","volume":"7","author":"ED Clarkson","year":"1995","journal-title":"Neuroreport"},{"issue":"6571","key":"ref51","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/380252a0","article-title":"Functional recovery in parkinsonian monkeys treated with GDNF","volume":"380","author":"DM Gash","year":"1996","journal-title":"Nature"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1038\/srep02786","article-title":"Autologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeys","volume":"3","author":"Z Ren","year":"2013","journal-title":"Sci Rep"},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.20374","article-title":"Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study","volume":"57","author":"NK Patel","year":"2005","journal-title":"Ann Neurol"},{"issue":"2","key":"ref54","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","article-title":"Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor","volume":"102","author":"JT Slevin","year":"2005","journal-title":"J Neurosurg"},{"issue":"1","key":"ref55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/mds.25108","article-title":"Animal models of Parkinson\u2019s disease: limits and relevance to neuroprotection studies","volume":"28","author":"E Bezard","year":"2013","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"ref56","first-page":"S16","article-title":"Functional models of Parkinson's disease: a valuable tool in the development of novel therapies","volume":"64","author":"P Jenner","year":"2008","journal-title":"Ann Neurol"},{"issue":"Suppl 4","key":"ref57","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S1353-8020(09)70829-6","article-title":"From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease","volume":"15","author":"P Jenner","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"issue":"s1","key":"ref58","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.3233\/JPD-179006","article-title":"The MPTP Story","volume":"7","author":"JW Langston","year":"2017","journal-title":"J Parkinsons Dis"},{"issue":"11","key":"ref59","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1177\/1535370215576313","article-title":"Parkinson's disease and enhanced inflammatory response","volume":"240","author":"I Stojkovska","year":"2015","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"ref60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2014.226","article-title":"The ongoing pursuit of neuroprotective therapies in Parkinson disease","volume":"11","author":"D Athauda","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"18","key":"ref61","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s40265-015-0497-4","article-title":"Disease-Modifying Drugs in Parkinson\u2019s Disease","volume":"75","author":"A Park","year":"2015","journal-title":"Drugs"},{"issue":"5","key":"ref62","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease No Evidence of Benefit","volume":"71","year":"2014","journal-title":"JAMA Neurol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0182019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T21:14:37Z","timestamp":1719350077000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0182019"}},"subtitle":[],"editor":[{"given":"Eliseo A","family":"Eugenin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,28]]},"references-count":62,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0182019","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,28]]}}}